Cantor Fitzgerald Issues Positive Forecast for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price

Key Points

• Cantor Fitzgerald raised Vertex Pharmaceuticals’ price target from $595 to $619 and maintained an “overweight” rating, implying 11.9% potential upside. The broader analyst consensus is “Moderate Buy,” with a $580.70 target price.
• Vertex’s latest quarter showed 11.8% year-over-year revenue growth to $3.44 billion, slightly exceeding estimates, but adjusted EPS of $4.76 missed expectations of $4.82.
• Investors are balancing portfolio growth and raised full-year revenue guidance against higher spending on product launches, research and development, and the Crinetics acquisition, which pressured earnings growth.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) had its target price hoisted by equities researchers at Cantor Fitzgerald from $595.00 to $619.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an "overweight" rating on the pharmaceutical company's stock. Cantor Fitzgerald's target price indicates a potential upside of 11.90% from the company's current price.

A number of other equities research analysts also recently issued reports on VRTX. Barclays upped their price target on shares of Vertex Pharmaceuticals from $615.00 to $617.00 and gave the company an "overweight" rating in a research note on Wednesday, August 5th. Daiwa Securities Group lifted their price target on Vertex Pharmaceuticals from $555.00 to $556.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Sanford C. Bernstein raised shares of Vertex Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, July 29th. Leerink Partners started coverage on Vertex Pharmaceuticals in a report on Monday, September 21st. They issued an "outperform" rating and a $594.00 price objective on the stock. Finally, Wall Street Zen lowered shares of Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $580.70.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $553.15 on Tuesday. The firm's fifty day moving average price is $523.32 and its 200-day moving average price is $479.96. Vertex Pharmaceuticals has a fifty-two week low of $403.16 and a fifty-two week high of $568.67. The stock has a market cap of $140.39 billion, a P/E ratio of 32.20, a price-to-earnings-growth ratio of 2.54 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts' consensus estimates of $4.82 by ($0.06). The company had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.42 billion. Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The company's revenue for the quarter was up 11.8% on a year-over-year basis. During the same period in the previous year, the firm posted $4.80 EPS. On average, analysts predict that Vertex Pharmaceuticals will post 16.74 earnings per share for the current year.

Institutional Trading of Vertex Pharmaceuticals

Large investors have recently bought and sold shares of the company. United Advisor Group LLC grew its position in Vertex Pharmaceuticals by 17.4% in the third quarter. United Advisor Group LLC now owns 633 shares of the pharmaceutical company's stock valued at $331,000 after acquiring an additional 94 shares during the period. Plancorp LLC acquired a new position in shares of Vertex Pharmaceuticals during the third quarter valued at $254,000. May Hill Capital LLC grew its position in shares of Vertex Pharmaceuticals by 4.2% during the 3rd quarter. May Hill Capital LLC now owns 643 shares of the pharmaceutical company's stock worth $336,000 after buying an additional 26 shares during the period. Ashton Thomas Private Wealth LLC lifted its stake in shares of Vertex Pharmaceuticals by 10.4% in the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 2,994 shares of the pharmaceutical company's stock valued at $1,565,000 after purchasing an additional 281 shares during the period. Finally, Calamos Wealth Management LLC boosted its stake in Vertex Pharmaceuticals by 13.0% during the 3rd quarter. Calamos Wealth Management LLC now owns 1,252 shares of the pharmaceutical company's stock worth $655,000 after acquiring an additional 144 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 11.8% year over year to $3.44 billion, exceeding the $3.42 billion analyst estimate. Growth was supported by continued strength in the cystic fibrosis franchise and increasing contributions from newer products, including CASGEVY and JOURNAVX. Vertex Q3 2026 Earnings Call Transcript
• Positive Sentiment: Vertex raised its full-year 2026 revenue guidance, citing broad-based portfolio growth and the successful completion of its Crinetics Pharmaceuticals acquisition. Management also highlighted its advancing pipeline and a developing nephrology franchise as future growth opportunities. Vertex Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: The transition from Trikafta to newer cystic fibrosis treatment Alyftrek continued to expand the franchise, while the ramp-up of recently launched medicines may diversify Vertex’s long-term revenue base. However, the company is investing heavily in these launches and in the Crinetics deal. Vertex Spends Its CF Growth on New Launches
• Negative Sentiment: Adjusted earnings were $4.76 per share, below analyst expectations of approximately $4.82–$4.92 and down from $4.80 a year earlier. The shortfall reflects increased spending on new product launches, research and development, and the Crinetics acquisition, limiting profit growth despite higher sales. Vertex Misses Q3 Earnings Estimates
• Negative Sentiment: Although full-year revenue guidance was increased, reports characterized the improvement as a light hike that fell short of some investor expectations. That combination—an earnings miss and limited guidance upside—helped pressure the stock despite the revenue beat. Vertex Yo-Yos on Mixed Third-Quarter Report

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.